Novartis Reports Q1 Earnings Miss; Maintains Full-Year 2026 Outlook

Novartis (NVS) reported first-quarter financial results that fell short of analyst expectations, characterized by declines in both core earnings and net sales. The results indicate a challenging start to the year for the healthcare leader. The company's core earnings per share (EPS) came in at $1.99, representing a 15% decline on a constant currency basis and a 13% drop in USD terms. This figure missed the consensus estimate by $0.08. Net sales for the period totaled $13.11 billion, a 1% year-over-year decrease (5% decline in constant currency), missing consensus by $0.37 billion. Despite the quarterly miss, Novartis reported a free cash flow of $3.3 billion. Management has chosen to maintain its long-term projections, reaffirming full-year 2026 guidance. The company expects net sales to grow in the low single-digits, while core operating income is projected to decline by a low single-digit percentage. Market participants will likely focus on the discrepancy between the immediate quarterly performance and the stable long-term outlook. The reaffirmation of guidance suggests that the company views the Q1 miss as a temporary fluctuation rather than a structural decline in its business model.